EGFR and ovarian carcinoma: These results are similar to a study of four EGFR-positive ovarian cancer cell lines (Sewell et al, 2002) where growth stimulation with TGFα, another ligand for EGFR, was completely inhibited by gefitinib concentrations of 0.3 μM and above.